Rinvoq, upadacitinib
Named-patient access overview. Rinvoq is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
This page is informational, not medical advice.
About Rinvoq
Rinvoq (upadacitinib) is a selective and reversible Janus kinase (JAK) inhibitor manufactured by AbbVie. In cellular assays it inhibits JAK1 preferentially over JAK2, JAK3, and TYK2, which translates into modulation of multiple inflammatory cytokine pathways including IL-6, interferon-gamma, and the common gamma-chain cytokines IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. By dampening the JAK-STAT signaling cascade inside immune cells, Rinvoq turns down the chronic inflammatory drive that produces clinical disease in rheumatology, dermatology, and gastroenterology.
Rinvoq carries US FDA approval across six indications: moderately-to-severely active rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, active non-radiographic axial spondyloarthritis, moderate-to-severe atopic dermatitis (adolescents and adults), moderately-to-severely active ulcerative colitis, and moderately-to-severely active Crohn's disease. Most adult indications use a 15 mg once-daily extended-release tablet, with higher induction doses for inflammatory bowel disease.
As a member of the JAK-inhibitor class, Rinvoq carries a US boxed warning covering the risk of serious infection, mortality, malignancy, major adverse cardiovascular events, and thrombosis based on a post-marketing study of another JAK inhibitor in rheumatoid arthritis. The label restricts use to patients who have had an inadequate response or intolerance to one or more TNF blockers, and prescribers screen for tuberculosis, hepatitis B and C, lipid status, and cardiovascular risk before and during therapy. Reserve Meds confirms that screening is on file before any shipment is coordinated.
Rinvoq is supplied as 15 mg, 30 mg, and 45 mg extended-release oral tablets. Storage is at room temperature between 2 and 30 degrees Celsius in the original blister, with no cold-chain requirement, which simplifies the logistics path into hot-climate destinations relative to refrigerated biologics.
How Reserve Meds coordinates Rinvoq
- Patient or treating physician submits a named-patient request through the Patient Portal.
- Clinical team verifies appropriateness of Rinvoq for the patient's indication, dose, and destination country.
- Treating physician issues a prescription with clinical justification, prior-biologic history, and infection screen.
- Country-specific named-patient or personal-import documentation is prepared in the destination language.
- Rinvoq is sourced from a DSCSA-compliant US specialty wholesaler with full serialized traceability.
- Shipment is coordinated under controlled ambient conditions to the patient's physician or hospital pharmacy.
- A named concierge stays with the case from intake through delivery confirmation.
Access by country
Reserve Meds publishes a detailed country deep-dive for Rinvoq in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, infection-screening expectations, and ambient logistics for the route into that country. Tap any country to read the full deep-dive.
Indications, in brief
Rheumatoid arthritis. In moderately-to-severely active rheumatoid arthritis, Rinvoq 15 mg once daily produces ACR20, ACR50, and ACR70 response rates that compete with or exceed leading biologics in head-to-head trials, including against adalimumab on a background of methotrexate. It is positioned for patients who have not responded adequately to TNF inhibitors or who cannot tolerate parenteral therapy and prefer an oral once-daily regimen.
Psoriatic arthritis. Active psoriatic arthritis combines peripheral joint inflammation, enthesitis, dactylitis, axial involvement, and skin disease. Rinvoq 15 mg once daily addresses each domain in patients who have had an inadequate response or intolerance to one or more biologic DMARDs.
Ankylosing spondylitis and non-radiographic axial spondyloarthritis. In axial disease, Rinvoq improves spinal inflammation on MRI, ASDAS and BASDAI scores, and physical function, with a profile that supports use after TNF or IL-17 inhibitor failure.
Atopic dermatitis. In moderate-to-severe atopic dermatitis in adolescents and adults, Rinvoq produces rapid and deep reductions in itch and EASI score, with a 15 mg or 30 mg once-daily option that allows dose titration to disease activity.
Ulcerative colitis and Crohn's disease. In inflammatory bowel disease, Rinvoq begins with a higher-dose induction phase (45 mg daily for UC, 45 mg daily for CD) followed by 15 mg or 30 mg maintenance, achieving clinical remission and endoscopic improvement including in biologic-experienced patients.
What every destination country asks for
Documentation we prepare always covers the same medical core: physician letter of medical necessity tied to the labeled indication, recent diagnostic confirmation (DAS28 or CDAI for RA, joint counts and skin assessment for PsA, MRI/X-ray for axial disease, EASI for atopic dermatitis, endoscopy summary for inflammatory bowel disease), prior-biologic history establishing TNF-inhibitor inadequacy where required, current infection screen including tuberculosis (interferon-gamma release assay or tuberculin skin test), hepatitis B and C serology, a baseline lipid panel, the prescription itself with strength and quantity, and the country-specific named-patient or personal-import application translated into the destination language.
Logistics and handling
Rinvoq travels under controlled ambient conditions with temperature logging across the supply chain. The hand-off to the destination physician or hospital pharmacy is documented with the temperature record, lot and serial number, and chain-of-custody signature. Because the product does not require refrigeration, transit time into hot-climate destinations is more forgiving than for monoclonal-antibody biologics, but the chain of custody remains a documented and audited element of every coordination.
Start a request for Rinvoq
Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, an indicative timeline, and a formal quote in your local currency and USD.
Reserved for you.